Elevated levels of circulating tumor DNA are associated with significantly worse disease-free survival in patients with early, locally advanced, or metastatic breast cancer, indicates a meta-analysis.
Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.
A nationwide study of Swedish breast cancer patients has demonstrated that receipt of fertility preservation significantly improves reproductive outcomes compared with the absence of such care.
Mammographic breast density is independently associated with lymphedema risk in women who undergo curative surgery for breast cancer and could be added to established risk factors to predict lymphedema severity, say researchers.
Using circulating tumor cell count to guide first-line treatment decisions in hormone receptor-positive, HER2-negative metastatic breast cancer could be a reliable alternative to a choice based on clinical features, research shows.
A survey of Italian breast cancer units has highlighted the severe impact of the global SARS-CoV-2 outbreak on the management of individuals with breast cancer.
Women with breast cancer who undergo immediate breast reconstruction with nipple- or skin-sparing mastectomy after neoadjuvant chemotherapy have similar outcomes to those who receive conventional mastectomy, researchers report.
The endothelial cell expression of phosphorylated–focal adhesion kinase could serve as a prognostic biomarker in women who receive neoadjuvant chemotherapy for locally advanced breast cancer, research suggests.
UK researchers have provided updated estimates of the risks for breast cancer associated with the use of various hormone replacement therapy preparations.
The addition of enzalutamide to exemestane may improve the progression-free survival of a subset of patients with HR-positive, HER2-negative, advanced breast cancer, study data suggest.
The addition of CDK4/6 inhibitors to endocrine therapy is associated with improved outcomes in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, shows a meta-analysis.
A prognostic model based on eight DNA repair-related genes may help identify women with breast cancer who are at high risk for death, Chinese researchers report.
Older women who are prescribed opioids within a year of finishing active treatment for breast cancer have an immediately elevated risk for serious adverse events, including, but not limited to, those associated with opioid misuse, suggests a review of medical records.
The addition of pembrolizumab to eribulin does not improve the survival outcomes of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, suggests a phase 2 study.
Early data suggest almost a third of patients with metastatic breast cancer could benefit from treatment with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan.
Pathologic complete response is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.
The addition of palbociclib to adjuvant endocrine therapy does not prolong invasive disease-free survival in hormone receptor-positive, HER2-negative, stage II–III breast cancer, shows the phase 3 PALLAS trial.
Combining atezolizumab with standard neoadjuvant chemotherapy achieves significantly higher pathologic complete response rates than chemotherapy alone in individuals with stage II–III triple-negative breast cancer, indicates the IMpassion031 trial.
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative, endocrine-sensitive, metastatic breast cancer, shows the phase 2 FLIPPER trial.